ASX Announcement

Successful Dosing of First Hong Kong Patient with RC220 Completes Recruitment of CPACS Trial Initial Dose Cohort

- Third patient safely dosed with RC220 in the cardioprotection and anticancer synergy (CPACS) Phase 1 trial at the Queen Mary Hospital, Hong Kong
- Recruitment completion enables initiation of the next dose level cohort, subject to Safety Review Committee (SRC) review
- Next cohort patients will be recruited from multiple sites in Australia, Hong Kong and South Korea using the updated trial protocol announced February 2026.

---

19 March 2026 – Racura Oncology Limited ('Racura') is pleased to announce the dosing of the third patient with RC220 in its CPACS Phase 1 clinical trial in advanced solid tumours at the first Hong Kong site. The patient was treated by Principal Investigator Dr Roland Ching-Yu Leung and his team at the Queen Mary Hospital. No phlebitis (vein inflammation) or any other adverse events were reported following dosing at 40mg/m^2 of RC220.

Third patient dosing follows successful first and second patient treatment at the Southside Cancer Care Centre (ASX Announcements: 1 May 2025; 2 September 2025). To date, no dose limiting toxicities have been observed in any patient in the study.

Dosing of the third patient also completes recruitment of the first trial cohort. In accordance with the trial protocol, the Safety Review Committee (SRC) will review all accumulated safety data collected from the three patients. Subject to SRC review and clearance, the trial will then progress to the next planned RC220 dose level of 80 mg/m^2 using the updated trial protocol announced 11 February 2026.

Racura Chief Executive Officer, Dr Daniel Tillett commented: *"The safe dosing of the third patient in our RC220 solid tumour trial in Hong Kong and recruitment of the first dose escalation cohort is an important milestone for Racura Oncology. We are grateful to all the patients, investigators, and clinical teams who have made this trial possible and we look forward to treating patients on the updated protocol."*

Racura's Phase 1 solid tumour clinical trial is open-label and is being conducted across multiple sites in Australia, Hong Kong, and South Korea. Stage 1 of the trial is using ascending doses of RC220 to determine the safety, tolerability, pharmacokinetics, and maximum tolerated combined dose (MTCD) of RC220 in combination with doxorubicin in up to 33 patients. Effects on a range of clinical biomarkers, including a blood-based measure of the cardioprotective mechanism of action of RC220, will also be examined (ASX announcement: 11 February 2026).

After interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients in Stage 2 for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The Phase 1 trial will use a Bayesian design, enabling greater trial flexibility and speed.

As the trial is open label in nature, patient outcomes will be obtained soon after patients are treated. Racura intends to announce progress updates on the trial on a regular basis, but not at the individual patient level.

-ENDS-

About Racura Oncology (ASX: RAC)

Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura Oncology has collaborated with Astex, Emory University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements please visit our Interactive Announcements page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@racuraoncology.com

Media contact:

Cherie Hartley +61 418 737 020
cherie.hartley@irdepartment.com.au